Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Pflug, Natali ^a,b   Kluth, Sandra ^a,b   Vehreschild, Jörg J ^a,c   Bahlo, Jasmin ^a,b   Tacke, Daniela ^a,c   Biehl, Lena ^a,c   Eichhorst, Barbara ^a,b   Fischer, Kirsten ^a,b   Cramer, Paula ^a,b   Fink, Anna Maria ^a,b   von Bergwelt Baildon, Michael ^a   Stilgenbauer, Stephan ^d   Hallek, Michael ^a,b   Cornely, Oliver A ^a,c,e   Vehreschild, Maria J G T ^a,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b German CLL Study Group (GCLLSG)   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antibiotics; chemotherapy; cisplatin; cyclophosphamide; microbiota

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; FLUDARABINE; RITUXIMAB;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; FEMALE; GRAM POSITIVE INFECTION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84969776957     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1150399     Document Type: Article

References (14)

1. W.J.van der Velden, A.H.Herbers, M.G.Netea, N.M.Blijlevens. Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. Br J Haematol 2014; 167:441-52; PMID:25196917; 10.1111/bjh.13113
2. M.J.Vehreschild, A.M.Meissner, O.A.Cornely, G.Maschmeyer, S.Neumann, M.von Lilienfeld-Toal, M.Karthaus, M.Wattad, P.Staib, M.Hellmich et al. Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. Haematologica 2011; 96:1855-60; PMID:21859736; 10.3324/haematol.2011.049627
3. N.Iida, A.Dzutsev, C.A.Stewart, L.Smith, N.Bouladoux, R.A.Weingarten, D.A.Molina, R.Salcedo, T.Back, S.Cramer et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342:967-70; PMID:24264989; 10.1126/science.1240527
4. S.Viaud, F.Saccheri, G.Mignot, T.Yamazaki, R.Daillere, D.Hannani, D.P.Enot, C.Pfirschke, C.Engblom, M.J.Pittet et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342:971-6; PMID:24264990; 10.1126/science.1240537
5. L.F.Lisboa, B.G.Miranda, M.B.Vieira, F.L.Dulley, G.G.Fonseca, T.Guimaraes, A.S.Levin, M.A.Shikanai-Yasuda, S.F.Costa. Empiric use of linezolid in febrile hematology and hematopoietic stem cell transplantation patients colonized with vancomycin-resistant Enterococcus spp. Int J Infect Dis 2015; 33:171-6; PMID:25660090; 10.1016/j.ijid.2015.02.001
6. M.Paul, Y.Dickstein, S.Borok, L.Vidal, L.Leibovici. Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev 2014; 1: 3914; PMID:24425445; 10.1002/14651858.CD003914.pub3
7. C.G.Buffie, V.Bucci, R.R.Stein, P.T.McKenney, L.Ling, A.Gobourne, D.No, H.Liu, M.Kinnebrew, A.Viale et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015; 517:205-8; PMID:25337874; 10.1038/nature13828
8. Y.Taur, R.R.Jenq, M.A.Perales, E.R.Littmann, S.Morjaria, L.Ling, D.No, A.Gobourne, A.Viale, P.B.Dahi et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014; 124:1174-82; PMID:24939656; 10.1182/blood-2014-02-554725
9. R.R.Jenq, C.Ubeda, Y.Taur, C.C.Menezes, R.Khanin, J.A.Dudakov, C.Liu, M.L.West, N.V.Singer, M.J.Equinda et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012; 209:903-11; PMID:22547653; 10.1084/jem.20112408
10. R.Jenq, Y.Taur, S.Devlin, D.Ponce, J.Goldberg, K.F.Ahr, E.R.Littmann, L.Ling, A.C.Gobourne, L.C.Miller et al. Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. Biol Blood and marrow Transplant 2015; 21:1373-83; PMID:25977230; 10.1016/j.bbmt.2015.04.016.
11. D.Weber, P.J.Oefner, A.Hiergeist, J.Koestler, A.Gessner, M.Weber, J.Hahn, D.Wolff, F.Stammler, R.Spang et al. Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. Blood 2015; 126:1723-8; PMID:26209659; 10.1182/blood-2015-04-638858
12. M.Hallek, K.Fischer, G.Fingerle-Rowson, A.M.Fink, R.Busch, J.Mayer, M.Hensel, G.Hopfinger, G.Hess, U.von Grunhagen et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376:1164-74; PMID:20888994; 10.1016/S0140-6736(10)61381-5
13. M.Hallek, B.D.Cheson, D.Catovsky, F.Caligaris-Cappio, G.Dighiero, H.Döhner, P.Hillmen, M.J.Keating, E.Montserrat, K.R.Rai, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Blood. 2008 Jun 15; 111(12):5446-56; 10.1182/blood-2007-06-093906.
14. B.D.Cheson, B.Pfistner, M.E.Juweid, R.D.Gascoyne, L.Specht, S.J.Horning, B.Coiffier, R.I.Fisher, A.Hagenbeek, E.Zucca et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86; PMID:17242396; 10.1200/JCO.2006.09.2403